èšåºæ®µéã®å
ç«è
«çåŠäŒæ¥ã§ãã Allogene Therapeutics, Inc. ã¯ãããæ²»çã®ããã®éºäŒåçµã¿æãåçš® T 现èçæ³ã®éçºãšåååãè¡ã£ãŠããŸããR/R CD19 éœæ§ B 现è ALL ã®å°å
ããã³æäººæ£è
ã®æ²»çãç®çãšããåçš®ãã¡ã©æååå®¹äœ (CAR) T 现è補ååè£ UCART19 ã®éçºã補é ãåååãè¡ã£ãŠããŸãããŸããR/R éããžãã³ãªã³ãè
«ã®æ²»çãç®çãšãã第 I çžèšåºè©Šéšäžã®æ CD19 åçš® CAR T 现è補ååè£ ALLO-501 ãšãR/R 倧现èå B 现èãªã³ãè
«ãŸãã¯åœ¢è³ªè»¢ææ¿Ÿèæ§ãªã³ãè
«ã®æ²»çãç®çãšãã第 I/II çžèšåºè©Šéšäžã® ALLO-501A ãéçºããŠããŸããããã«ãR/R å€çºæ§éªšé«è
«ã®æ²»çãç®çãšãã第 I çžèšåºè©Šéšäžã®åçš® CAR T 现è補ååè£ ALLO-715 ãéçºäžã§ããæ¥æ§éªšé«æ§çœè¡ç
ã®æ²»çãç®çãšããåçš®CAR T现è補ååè£ã®ALLO-819ãå€çºæ§éªšé«è
«ã®æ²»çãç®çãšããåçš®CAR T现è補ååè£ã®ALLO-605ãæCD52ã¢ãã¯ããŒãã«æäœã®ALLO-647ãè
现èããã®æ²»çãç®çãšããCD70ãå°çްèèºããããã³ãã®ä»ã®æªæ§ç¥çµå
åæ³è
«çã®æ²»çãç®çãšããDLL3ãå瀟ã¯ããã¡ã€ã¶ãŒç€Ÿãã»ã«ãŽã£ãšç€Ÿãã»ã«ã¬ã¯ãã£ã¹ç€Ÿããããã»ã»ã©ãã¥ãŒãã£ã¯ã¹ç€Ÿãšã©ã€ã»ã³ã¹å¥çŽããã³ååå¥çŽãç· çµããŠããã»ããã¹ããªã³ã°ã¯ãŒã¯ã¹ã»ã»ã©ãã¥ãŒãã£ã¯ã¹ç€Ÿãšèšåºè©Šéšååå¥çŽãç· çµããŠããããŸãããããµã¹å€§åŠMDã¢ã³ããŒãœã³ããã»ã³ã¿ãŒãšãåçš®CAR T现è補ååè£ã®åèšåºããã³èšåºè©Šéšã«é¢ããæŠç¥çååå¥çŽãç· çµããŠãããå瀟ã¯2017幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ãµãŠã¹ãµã³ãã©ã³ã·ã¹ã³ã«æ¬ç€Ÿã眮ããŠããã